Nutriband Inc (NTRB NASDAQ) stock market data APIs
$6.59
-0.75(-10.2%)
as of January 22, 2025
Nutriband Inc Financial Data Overview
Price chart is built with
Anychart
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Prev. Close
7.34
Open
6.59
Volume
4 344 K
High
8.18
Low
6.21
52 wk Range
2.22-9.595
Market Cap
81 520 K
Shares Outstanding
11 106 K
Revenue
2 017 K
EPS
-0.1227
Beta
0.416
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nutriband Inc data using free add-ons & libraries
Get Nutriband Inc Fundamental Data
Nutriband Inc Fundamental data includes:
- Net Revenue: 2 017 K
- EBITDA: -5 461 903
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-12-10
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nutriband Inc News
New
Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings
ORLANDO, FL / ACCESSWIRE / July 27, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its consumer sp...
Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission
Company targeting FDA submission in the first half of 2024 AVERSA™ Fentanyl is the flagship product of the Company's AVERSA™ Platform ORLANDO, FL / ACCESSWIRE / July 14, 2023 / Nutriband Inc. ("...
Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology
ORLANDO, FL / ACCESSWIRE / June 23, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from t...
Nutriband to Attend 2023 BIO International Convention
ORLANDO, FL / ACCESSWIRE / May 10, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it will be attending the Biotechnology In...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
